Category Archives: Investment

MannKind’s 10-year quest for insulin product Afrezza gets last-ditch chance; time to buy, or run?

The News: Last week, MannKind Corp. (Nasdaq:MNKD) led advancing stocks in the healthcare sector, soaring 151% to $5.03, after saying it won a labeling concession from the FDA on its Afrezza inhalable… Read more »

Catabasis soars on fresh Duchenne trial data, proving biotech melt-up still in progress; but for how much longer?

The News: Recuperating from a trial flop involving its lead drug for Duchenne muscular dystrophy, Catabasis Pharmaceuticals Inc. (Cambridge MA) is charging ahead with a late-stage study, hyping new data… Read more »

Senators seek probe of Allergan’s patent sale to Mohawk Tribe; could Tesla do the same with its battery patents?

The News: Four senators are demanding an investigation of Allergan PLC’s (Dublin IRL) first-of-a-kind patent deal with the Saint Regis Mohawk Tribe, alleging the move to protect Restasis is another… Read more »

Alnylam soars on RNAi success as Phase 3 patisiran study hits all goals; market overreacts as pipeline unproven and competition lurks.

The News: Alnylam Pharmaceuticals Inc.’s (Cambridge MA) RNAi-based drug that targets a rare genetic disease cleared a key study, in a breakthrough for the new class of medicines that works… Read more »

Zai Lab’s U.S. IPO marks another white-hot Chinese offering that begs the question: why are these Asian offerings so special?

The News: Shang­hai-based biotech Zai Lab Ltd. raised $150 mil­lion from its up­sized IPO last Wednes­day (September 20, 2017), sell­ing 8.3 mil­lion shares at $18 each. After trad­ing began, the… Read more »

Weekly stock roundup: Marinus, McKesson are Buys, but not for everyone.

Marinus Pharmaceuticals Inc. (Nasdaq:MRNS) was among the top advancing issues last week, soaring 31% to $4.10. Investors pounced on shares after the Radnor, PA-based drugmaker announced that top-line data from… Read more »

Slumbering giant Lilly to cut more jobs, take a $1.2-billion hit to bolster R&D pipeline.

The News: Eli Lilly & Co. (Indianapolis IN) last week said it would lay off about 8% of its employees as the drugmaker, which has suffered setbacks over the past… Read more »

Stock round-up features superb week for Insmed and NewLink; not so much for Cellectis.

Insmed Inc. (Nasdaq:INSM) led advancing issues, more than doubling (+146%) over the week, to $30.25 as of Tuesday morning, September 12. The explosion began after the company announced that its… Read more »

Health stocks soar going into Labor Day weekend; well, not everyone. Here’s my take on three big movers: Abeona, UroGen and Otonomy.

Abeona Therapeutics Inc. (Nasdaq:ABEO) led advancing issues, soaring 57% over the week to $14.20 as of close Tuesday, Sept. 5. That huge gain resulted primarily from the US Food and… Read more »

Intra-Cellular shares zoom higher; is buying this name a gamble or a rational bet?

The News: Intra-Cellular Therapies Inc. (Nasdaq:ITCI) rocketed 41% over the past week to $15.70 on a positive regulatory update from the US Food and Drug Administration regarding its lumateperone treatment for schizophrenia…. Read more »